Dyadic International (NASDAQ:DYAI) Issues Earnings Results

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), FiscalAI reports. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.02 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic reported expanding commercialization, including product shipments through IBT Bioservices, initial direct sales, and partner products generating commercial sales. Management expects revenue growth to build across life sciences, food and nutrition, and bioindustrial markets, although the near-term ramp is expected to be lumpy.
• An initial pilot-scale run for animal-free recombinant human transferrin increased productivity by approximately 80%, which management estimates could reduce manufacturing costs by about 40% and improve scalability and commercial economics.
• Externally funded biopharmaceutical programs continue to validate the C1 platform, including monoclonal antibody work and vaccine-antigen production completed in approximately 15 days from plasmid to purified protein. These programs could support future licensing, milestone, royalty, and strategic partnership opportunities.
• Dyadic ended Q2 with approximately $4.8 million in cash, and management disclosed substantial doubt about its ability to continue as a going concern without additional capital. The company is evaluating equity, non-dilutive, licensing, partnership, and other financing alternatives.
• Second-quarter revenue was essentially flat year over year at approximately $961,000, while the net loss widened to approximately $2.1 million from $1.8 million. Cost of revenue and general and administrative expenses increased, despite lower internal R&D spending.

Dyadic International Price Performance

NASDAQ DYAI traded down $0.09 on Thursday, reaching $0.79. The company’s stock had a trading volume of 177,684 shares, compared to its average volume of 181,080. Dyadic International has a twelve month low of $0.65 and a twelve month high of $1.60. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The firm’s 50 day moving average is $0.97 and its two-hundred day moving average is $0.86. The stock has a market cap of $28.64 million, a PE ratio of -3.42 and a beta of 1.12.

Hedge Funds Weigh In On Dyadic International

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Dyadic International in the 3rd quarter valued at approximately $190,000. Finally, Geode Capital Management LLC increased its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.